Chardan Capital Maintains Buy on Dyne Therapeutics, Raises Price Target to $42
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital has maintained its Buy rating on Dyne Therapeutics (NASDAQ:DYN) and raised the price target from $31 to $42.
May 21, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Chardan Capital has maintained its Buy rating on Dyne Therapeutics and increased the price target from $31 to $42, indicating strong confidence in the company's future performance.
The increase in the price target from $31 to $42 by Chardan Capital suggests a positive outlook for Dyne Therapeutics. This is likely to boost investor confidence and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100